U.S. markets closed

Ultimovacs ASA (7UM.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
7.10+0.05 (+0.71%)
At close: 09:16AM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.05
Bid6.92 x N/A
Ask7.18 x N/A
Day's Range7.10 - 7.10
52 Week Range5.92 - 16.50
Avg. Volume0
Market Cap242.975M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-0.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for 7UM.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation

      Oslo, 12 August 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its second quarter 2022 results on Friday 19 August 2022. The presentation can be followed as a live webcast accessed through a link on at 09:00 CET on Friday 19 August 2022. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation th

    • GlobeNewswire

      Ultimovacs ASA: Mandatory notification of trade by primary insider

      Oslo, 30 June 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK 69.50 per share. Following this transaction, Carlos de Sousa and closely related parties hold 18,056 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Secu

    • GlobeNewswire

      Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

      Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 monthsStudy provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces the completed recruitment of 154 patients in the INITIUM trial. INITIUM is Ultimovacs’ Phase II clinical trial of its universal cancer